Co-Authors
This is a "connection" page, showing publications co-authored by Delia Goletti and Elisa Petruccioli.
Connection Strength
2.345
-
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. J Transl Med. 2021 06 26; 19(1):272.
Score: 0.953
-
In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. Biomed Res Int. 2021; 2021:8856018.
Score: 0.238
-
Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. Int J Infect Dis. 2021 May; 106:338-347.
Score: 0.235
-
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S82-S87.
Score: 0.233
-
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021 04; 82(4):58-66.
Score: 0.233
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.227
-
Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
Score: 0.226